In an in-depth interview with BioSpectrum Asia, Novotech’s Director of Therapeutic Strategy, Tom Hickey, shared strategic insights from over 90 Hepatitis B clinical projects conducted across global markets.
Key takeaways:
- Strategic Site & Patient Selection: Success is driven by identifying the right patient populations and leveraging high-performing clinical sites with strong regional expertise.
- Regulatory Foresight: Early engagement with global regulatory agencies helps streamline approvals, particularly in regions leading innovation in chronic Hepatitis B (CHB) treatments.
- Adaptability to Scientific Advances: Novotech incorporates the latest biomarkers, assays, and treatment approaches into trial protocols to keep pace with the evolving therapeutic landscape.
- Patient Retention Excellence: With CHB studies often running for several years, Novotech applies robust patient engagement strategies—including digital tools and community support—to maintain high retention rates.
Tom Hickey also outlined key challenges in CHB trials, such as recruitment difficulties in under-researched geographies and complexities related to specific patient subtypes. Novotech’s global footprint across Asia Pacific, Central Asia, Eastern Europe, and North America, along with a network of 350+ CHB investigators, enables the company to meet these challenges head-on.
As personalized medicine reshapes HBV treatment, Novotech is integrating genomic screening, real-world data, biomarker-driven patient stratification, and adaptive trial designs to accelerate development timelines and improve outcomes.
Novotech remains at the forefront of Hepatitis B clinical research, combining global trial execution expertise with deep regional insights to support biotech sponsors in delivering transformative therapies.